Grow Your Pharma Business Digitally
Market Place
Post Enquiry
Capability
01 Early Clinical / Phase I-IIa (1)
Country
01 U.S.A (1)
- Service Details
AVM Biotechnology is actively enrolling patients in an open-label adaptive design expansion cohort pivotal phase 1/2 study in relapsed/refractory non-hodgkin’s lymphoma and leukemia at major cancer treatment centers in the US.
- Directory Listing
Pharma Service: Clinical Trials
Sub Category: Phase I / IIa